Reports on Clinical Trial Research from Huntsman Cancer Institute Provide New Insights (18f-labeled Fluoroestradiol Pet/ct: Current Status, Gaps In Knowledge, and Controversies-ajr Expert Panel Narrative Review).

A recent study from the Huntsman Cancer Institute in Salt Lake City, Utah, explores the use of 18F-labeled Fluoroestradiol PET/CT imaging for tissues expressing estrogen receptors, particularly in ER-positive breast cancer cases. The research discusses the current status, gaps in knowledge, and controversies surrounding the use of FES PET/CT, including its clinical applications, image interpretation, and potential future directions. The study highlights the need for further research on the use of FES PET/CT for non-breast malignancies expressing estrogen receptors, and emphasizes the importance of ongoing clinical trials to expand its clinical use. [Extracted from the article]